MSD has secured an exclusive worldwide license from LaNova Medicines for developing, manufacturing, and commercialising the latter’s new investigational programmed cell death 1 (PD-1)/vascular ...
in patients who failed therapy with drugs targeting vascular endothelial growth factor (VEGF). Sodhi and his ...
GlobalData on MSN1d
BioNTech signs agreement to acquire BiotheusBioNTech has signed a definitive agreement to acquire Biotheus to obtain complete worldwide rights to BNT327/PM8002, a ...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and LaNova Medicines Ltd. (LaNova), a privately held ...
To combat this, doctors prescribe medications that slow the growth of new blood vessels, called anti-VEGF (vascular ...
Merck & Co. has struck a licensing deal with LaNova Medicines that is potentially worth more than $3 billion to the clinical-stage biotechnology company.
An RNA-editing gene therapy has been developed that switches off the key driver of common eye conditions affecting diabetics ...
MEDIA RELEASEAfqlir® (aflibercept) approved to treat various retinal diseases, including neovascular age-related macular degeneration (nAMD)One ...
Nov 2024 - Opthea (ASX:OPT) has announced a boost to its cash reserves, receiving a $15.9m research and development tax ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback